Trial Profile

A phase I/II trial of FWD1509 in patients with advanced non-small cell lung cancer

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 15 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FWD 1509 (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Forward Pharma

Most Recent Events

15 Oct 2021 New trial record
19 Aug 2021 According to a Forward Pharma media release, the company received the Center for Drug Evaluation (CDE) of the National Food and Drug Administration of China approval for clinical development of FWD1509 in china.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com